Innate Immunotherapeutics today announced that the dose confirmation part of the company's Phase 2A trial of drug candidate MIS416 in patients with the progressive form of MS will commence in early January 2012.

John Key officially opens the Don Beaven Medical Research Centre

Following the Christchurch earthquake Primorus has provided business continuity and disaster recovery to fellow Christchurch sites in the form of staffing and secure facilities to phase I certified standards.

This vital service has provided safety and continuity for subjects and pharmaceutical companies in line with our strategic goals of increasing quality and furthering research in New Zealand.

Managing Director of Primorus Clinical Trials, Matt Kepple, presents at NZBIO session: Clinical Development in NZ - Why NZ is Good for Trials and Why Trials are Good for NZ

Primorus Clinical Trials has re-opened following the Canterbury earthquake.

We would like to say a huge THANK YOU to all our brilliant staff, clients and volunteers during this difficult time, we have had remarkable support from everyone and are indebted to the fantastic emergency services in Christchurch as well as those providing infrastructure services.

Primorus is the first site in New Zealand to be awarded the TSANZ and ANZSRS certification in Spirometry for technicians.

Ruth Beran of Radio New Zealand National visited Primorus to record a story on early phase clinical research. The program will air on Wednesday 30 June on Radio New Zealand National at 3:45pm and from 9pm on Thursday 1 July on Our Changing World.